A biobased binder technology that converts polysaccharide-rich pectin production side streams into functional adhesives for engineered wood products. The approach eliminates the need for separation and purification of individual constituents, transforming a low-value residual stream into an industrial input while reducing processing costs compared to refined biopolymer binders.
This research develops a biobased binder technology for engineered wood products using polysaccharide-rich side streams generated during pectin production. These heterogeneous residual streams contain cellulose, hemicellulose, residual pectin, and protein — all established components of biobased wood adhesives. The key innovation is that the side stream can be used directly as the primary binder component without requiring separation and purification of its individual constituents, potentially converting a low-value residual stream into a functional industrial input while reducing the processing burden associated with refined biopolymer binders.
The binder is evaluated in both aqueous and dry formulations, comparing wet application with dry blending into wood feedstocks. Key technical aspects include:
This technology is at an early research stage. The research hypothesis is supported by prior demonstrations that heterogeneous, minimally refined biological matter can form strong adhesives for lignocellulosic substrates. Planned validation will evaluate bonding performance across varied formulations and feedstock conditions, progressing toward representative panel fabrication and benchmarking against commercial binders.
The University of Washington is a large public research university with campuses in Seattle, Bothell, and Tacoma, known for a broad portfolio from fundamental discovery to applied innovation. Industry partners engage through a South Lake Union research campus adjacent to a major life sciences district and through collaboration programs that place faculty and students alongside corporate R&D. The university’s integration with a major academic health system enables clinical translation and large-scale trials. Research is supported by competitive federal funding from NIH, NSF, DOE, and DoD. A dedicated technology transfer office manages IP, licensing, and startup incubation with prototyping resources.